Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124258) titled 'Surufatinib Combined with Octreotide Microspheres as First-Line Therapy in Surgically Unresectable or Metastatic Neuroendocrine Tumors: A Phase II, Single-Arm, Single-Center Clinical Study' on May 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital &Institute)
Condition:
Metastatic or surgically unresectable neuroendocrine tumors
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-05-15
Target Sample Size: Experimental Group:20;
Countries of Recruitment...